RA
TAK icon

Reby Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Reby Advisors’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$1K Buy
+75
New +$1.32K ﹤0.01% 581

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM

Reby Advisors's TAK Position: Q4 2020 in Review

Reby Advisors opened a new position in Takeda Pharmaceutical (TAK) in Q4 2020: 75 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #581 among its holdings.

312 funds tracked by Wall St. Rank hold TAK as of Q4 2020.

  • Reby Advisors held 75 shares of Takeda Pharmaceutical worth $1K as of Q4 2020.
  • Takeda Pharmaceutical was a new Reby Advisors position in Q4 2020.
  • Takeda Pharmaceutical made up ﹤0.01% of Reby Advisors's portfolio in Q4 2020, its #581 holding.
  • 312 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2020.

Based on Reby Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.